Literature DB >> 21824992

Abilities of candesartan and other AT(1) receptor blockers to impair angiotensin II-induced AT(1) receptor activation after wash-out.

Yoshihiro Kiya1, Shin-ichiro Miura, Yoshino Matsuo, Sadashiva S Karnik, Keijiro Saku.   

Abstract

Angiotensin II (Ang II) binds to Ang II type 1 (AT(1)) receptor and evokes cell signaling, and subsequently stimulates vasoconstriction and cell proliferation, which eventually lead to cardiovascular disease. Since most AT(1) receptor blockers (ARBs) have molecular (differential) effects, we evaluated the specific features of candesartan and compared the abilities of candesartan and other ARBs (olmesartan, telmisartan, valsartan, irbesartan and losartan) to bind to and activate AT(1) receptors using a cell-based wash-out assay. Each ARB blocked Ang II-induced extracellular signal-regulated kinase (ERK) activation and inositol phosphate production to different degrees after wash-out. In addition, a small difference in the molecular structure, i.e. a carboxyl group, between candesartan and candesartan-7H was associated with a difference in the degree of this blocking effect. In addition, interaction between Gln(257) in the AT(1) receptor and the carboxyl group of candesartan may be partially associated with the effect of candesartan after wash-out. Although our findings regarding the molecular effects of ARB are based on basic research, these findings may lead to an exciting new area in the clinical application of ARBs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21824992      PMCID: PMC3891522          DOI: 10.1177/1470320311417478

Source DB:  PubMed          Journal:  J Renin Angiotensin Aldosterone Syst        ISSN: 1470-3203            Impact factor:   1.636


  20 in total

1.  Inverse agonism and neutral antagonism at alpha(1a)- and alpha(1b)-adrenergic receptor subtypes.

Authors:  O Rossier; L Abuin; F Fanelli; A Leonardi; S Cotecchia
Journal:  Mol Pharmacol       Date:  1999-11       Impact factor: 4.436

2.  Constitutively active homo-oligomeric angiotensin II type 2 receptor induces cell signaling independent of receptor conformation and ligand stimulation.

Authors:  Shin-Ichiro Miura; Sadashiva S Karnik; Keijiro Saku
Journal:  J Biol Chem       Date:  2005-03-03       Impact factor: 5.157

Review 3.  Structure-activity relationships of inverse agonists for G-protein-coupled receptors.

Authors:  Willem Soudijn; Ineke van Wijngaarden; Adriaan P Ijzerman
Journal:  Med Res Rev       Date:  2005-07       Impact factor: 12.944

4.  Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist.

Authors:  M Noda; Y Shibouta; Y Inada; M Ojima; T Wada; T Sanada; K Kubo; Y Kohara; T Naka; K Nishikawa
Journal:  Biochem Pharmacol       Date:  1993-07-20       Impact factor: 5.858

5.  Different types of receptor interaction of peptide and nonpeptide angiotensin II antagonists revealed by receptor binding and functional studies.

Authors:  W Wienen; A B Mauz; J C Van Meel; M Entzeroth
Journal:  Mol Pharmacol       Date:  1992-06       Impact factor: 4.436

6.  Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor.

Authors:  Shin-ichiro Miura; Masahiro Fujino; Hiroyuki Hanzawa; Yoshihiro Kiya; Satoshi Imaizumi; Yoshino Matsuo; Sayo Tomita; Yoshinari Uehara; Sadashiva S Karnik; Hiroaki Yanagisawa; Hiroyuki Koike; Issei Komuro; Keijiro Saku
Journal:  J Biol Chem       Date:  2006-05-10       Impact factor: 5.157

Review 7.  Review: angiotensin II type 1 receptor blockers: class effects versus molecular effects.

Authors:  Shin-ichiro Miura; Sadashiva S Karnik; Keijiro Saku
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2010-07-05       Impact factor: 1.636

8.  Role of aromaticity of agonist switches of angiotensin II in the activation of the AT1 receptor.

Authors:  S Miura; Y H Feng; A Husain; S S Karnik
Journal:  J Biol Chem       Date:  1999-03-12       Impact factor: 5.157

9.  Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.

Authors:  Marc A Pfeffer; Karl Swedberg; Christopher B Granger; Peter Held; John J V McMurray; Eric L Michelson; Bertil Olofsson; Jan Ostergren; Salim Yusuf; Stuart Pocock
Journal:  Lancet       Date:  2003-09-06       Impact factor: 79.321

10.  "Network leaning" as a mechanism of insurmountable antagonism of the angiotensin II type 1 receptor by non-peptide antagonists.

Authors:  Takanobu Takezako; Camelia Gogonea; Yasser Saad; Keita Noda; Sadashiva S Karnik
Journal:  J Biol Chem       Date:  2004-01-30       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.